News Search Results
Jul 01, 2026, 08:50 ET Biotech Startup Turns to Space to Manufacture Artificial Retinas for Treating Blindness
lossKENNEDY SPACE CENTER, Fla., July 1, 2026 /PRNewswire/ -- A biotechnology startup is harnessing the unique space environment to manufacture artificial retinas that could one day restore vision to the millions of people
More news about: International Space Station National Lab
Jul 01, 2026, 08:05 ET Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
Calif., July 1, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the appointment of Alison L. Hannah, M.D. to the role of Executive Vice President
More news about: Rigel Pharmaceuticals, Inc.
Jul 01, 2026, 08:00 ET ARTAN Bio Closes $1 Million Seed Round to Advance its tRNA Platform Toward Human Studies
ARTAN Bio, a longevity biotechnology company based in St. Petersburg, Florida, today announced the close of a $1 million seed round led by company co-founder Michael Torres, Ph.D.,
More news about: ARTAN BIO
Jul 01, 2026, 08:00 ET MiDOG Animal Diagnostics Launches First Dedicated NGS-Based Parasite Detection Test for Veterinary Medicine
parasite genomics. Through research and collaboration efforts, MiDOG has contributed genomic resources to publicly available National Center for Biotechnology Information databases, including a significant portion of publicly available thorny-headed worm and flatworm genomes. These resources help strengthen
More news about: MiDOG Animal Diagnostics
Jul 01, 2026, 08:00 ET Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
July 1, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system
More news about: Intensity Therapeutics Inc.
Jul 01, 2026, 08:00 ET Apnimed Strengthens Leadership Team with Appointments of Industry Veterans Michael Kelly as Chief Financial Officer and Steven Spector as Chief Legal Officer and Head of Corporate Affairs
commercial-stage organization.Mr. Spector brings to Apnimed more than 25 years of legal, compliance and business development experience in the biotechnology industry, further strengthening Apnimed's legal and compliance capabilities as the company prepares for the potential commercial launch of AD109
More news about: Apnimed, Inc.
Jul 01, 2026, 07:00 ET Remepy Publishes New Evidence Showing its Hybrid Drug, Hybridopa™, Effect on Structural Connectivity in the Brain of Parkinson's Patients Associated with Improved Clinical Outcome
investigational product and has not yet been approved by the FDA or any regulatory authority.About RemepyRemepy is a clinical-stage biotechnology company pioneering Hybrid Drugs™, a new class of drugs combining traditional drugs with personalized, AI-driven therapeutic apps. Remepy partners
More news about: Remepy
Jul 01, 2026, 03:00 ET SkylineDx's Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care
www.merlinmelanomatest.com.About SkylineDxSkylineDx is a biotechnology company focused on research and development of molecular diagnostics in oncology, and inflammatory and infectious diseases. SkylineDx uses its expertise
More news about: SkylineDx
Jun 30, 2026, 19:00 ET Colossal Foundation and University of Tasmania Partner to Combat Devil Facial Tumour Disease with Vaccines and Gene Editing
The collaboration leverages Colossal's marsupial de-extinction and conservation biotechnology platform to save the Tasmanian devil from a contagious cancer that has driven 80% population declines across TasmaniaDALLAS and HOBART, Australia,
More news about: Colossal Biosciences Inc.
Jun 30, 2026, 16:02 ET Halozyme Appoints David Ramsay as President Drug Delivery
the acceleration of value creation for our shareholders."Mr. Ramsay brings more than 30 years of strategic financial leadership across the biotechnology and life sciences sectors, including extensive experience in capital markets, corporate finance, investor relations, and operational scale‑up.David
More news about: Halozyme Therapeutics, Inc.
Jun 30, 2026, 10:27 ET Rescue Hearing Inc. Marks Major Milestone as MED-EL Acquires Two Gene Therapy Programs Targeting Genetic Hearing Loss and Balance Disorders
continue their cooperation. About Rescue Hearing Inc. Rescue Hearing Inc. is a biotechnology company focused on the development of genetic therapies for hearing and balance disorders, with research aimed at addressing underlying biological
More news about: Rescue Hearing Inc.
Jun 30, 2026, 09:13 ET Shantha Biologics Announces Cartridge Fill-Finish Collaboration
manufacturing. The company operates purpose-built sterile fill-finish capacity, including cartridge filling, and partners with global pharmaceutical and biotechnology companies to deliver high-quality development and aseptic manufacturing that meets international quality and compliance standards.Media
More news about: Shantha Biologics
Jun 30, 2026, 09:09 ET Shantha Biologics Announces Cartridge Fill-Finish Collaboration
manufacturing. The company operates purpose-built sterile fill-finish capacity, including cartridge filling, and partners with global pharmaceutical and biotechnology companies to deliver high-quality development and aseptic manufacturing that meets international quality and compliance standards.Media
More news about: Shantha Biologics
Jun 30, 2026, 09:03 ET Aspen Neuroscience Announces Completion of Cohort 3 and 4 Dosing in Aspiro Phase 1/2a Trial of Sasineprocel for Parkinson's Disease
DIEGO, June 30, 2026 /PRNewswire/ -- Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, today announced completion of dosing in Cohort 3 and Cohort 4 of its ongoing Phase 1/2a
More news about: Aspen Neuroscience, Inc.
Jun 30, 2026, 09:00 ET Bota Biosciences and BASF Introduce Bio-Identical Collagen III Powered by AI
market.About Bota BiosciencesBota Biosciences is a global leader in Physical AI-driven biomanufacturing, dedicated to making biotechnology a reliable and scalable engine of productivity. By integrating end-to-end capabilities in AI, synthetic biology, and industrialization, Bota pioneers
More news about: Bota Biosciences
Jun 30, 2026, 08:42 ET Will Therapeutics Announces CQDM-Backed Research Collaboration to Advance First Targeted Pharmacological Treatment for Anorexia Nervosa and Other Compulsive Disorders
MONTRÉAL, June 30, 2026 /PRNewswire/ -- Will Therapeutics, an early-stage biotechnology company developing novel small-molecule medicines for psychiatric and compulsive disorders, today announced that its collaborative research project
More news about: Will Therapeutics
Jun 30, 2026, 08:30 ET FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
HOUSTON, June 30, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts
More news about: FibroBiologics, Inc.
Jun 30, 2026, 08:30 ET Alexandria Real Estate Equities, Inc. Releases 2025 Corporate Responsibility Report Highlighting Strategic Integration of Mission, Innovation and Long-Term Value Creation
and lasting impact on society."More than five decades after Genentech's pioneering work in recombinant DNA technology helped catalyze the biotechnology revolution, the need for innovation to address significant unmet medical need remains immense, with more than 90% of the 10,000 known diseases still
More news about: Alexandria Real Estate Equities, Inc.
Jun 30, 2026, 08:22 ET Martis Capital, Healthcare-Focused PE Firm, Acquires Majority Stake in Healthcare Marketing, Communications, and Media Agency Deerfield Group
GroupDeerfield Group is a fully integrated marketing, media, communications, and technology agency providing innovative solutions for pharmaceutical, biotechnology, health tech, and consumer health companies. Deerfield's solutions are designed to meet the unique needs of healthcare organizations at all stages
More news about: Martis Capital
Jun 30, 2026, 08:00 ET DEERFIELD GROUP ANNOUNCES STRATEGIC INVESTMENT FROM MARTIS CAPITAL TO FUEL NEXT PHASE OF GROWTH
GroupDeerfield Group is a fully integrated marketing, media, communications, and technology agency providing innovative solutions for pharmaceutical, biotechnology, health tech, and consumer health companies. Deerfield's solutions are designed to meet the unique needs of healthcare organizations at all stages
More news about: Deerfield Group
Jun 30, 2026, 07:05 ET Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, announces cUHDRS subcomponent data from the twelve-month interim
More news about: Skyhawk Therapeutics
Jun 30, 2026, 07:00 ET Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, announces cUHDRS subcomponent data from the twelve-month interim
More news about: Skyhawk Therapeutics
Jun 30, 2026, 07:00 ET Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth
chain engagement. The company operated career development programs in partnership with leading educational institutions to help cultivate future biotechnology talent, while also advancing professional growth and leadership opportunities for women in its workforce. The company also expanded supplier sustainability
More news about: Samsung Biologics
Jun 30, 2026, 07:00 ET Muna Therapeutics Announces CEO Transition as Clinical Pipeline Advances
COPENHAGEN, Denmark and BOSTON, June 30, 2026 /PRNewswire/ -- Muna Therapeutics (Muna), a biotechnology company pioneering novel therapeutics for neurodegenerative diseases, today announced a CEO transition. Rita Balice-Gordon, Ph.D., Muna's founding
More news about: Muna Therapeutics
Jun 30, 2026, 06:30 ET Cytonics Completes First-In-Human Phase 1 Clinical Study Report for CYT-108, Advancing Program Toward Next Phase of Development.
of Cytonics. "Advancing a novel biologic from concept through a successful first-in-human clinical trial is a significant achievement for any biotechnology company. The completion of this report provides the foundation for our next regulatory interactions and advances our preparations for additional
More news about: Cytonics Corporation